Eagle Pharmaceuticals, Inc. (EGRX) announced the FDA has granted Qualified Infectious Disease Product Designation and Fast Track Designation for CAL02, a non-biological bacterial virulence neutralizer, anti-infective agent being developed to treat severe community-acquired bacterial pneumonia as an add-on therapy to standard of care.